EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High Grade Glioma Amenable for Nanotherapeutic Delivery

Adenike O Adekeye, David Needham iD, Ruman Rahman iD

Pharmaceutics · 10.02.2023 · 15 (2) · 599

DOI: 10.3390/pharmaceutics15020599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 10.02.2023. Verfasst von Adenike O Adekeye und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mr. Michael Hodgkinson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic reprogramming, through increased uptake of cholesterol in the form of low-density lipoproteins (LDL), is one way by which cancer cells, including high grade gliomas (HGG), maintain their rapid growth. In this study, we determined LDL receptor (LDLR) expression in HGGs using immunohistochemistry on tissue microarrays from intra- and inter tumour regions of 36 adult and 133 paediatric patients to confirm LDLR as a therapeutic target. Additionally, we analysed expression levels in three representative cell line models to confirm their future utility to test LDLR-targeted nanoparticle uptake, retention, and cytotoxicity. Our data show widespread LDLR expression in adult and paediatric cohorts, but with significant intra-tumour variation observed between the core and either rim or invasive regions of adult HGG. Expression was independent of paediatric tumour grade or identified clinicopathological factors. LDLR-expressing tumour cells localized preferentially within perivascular niches, also with significant adult intra-tumour variation. We demonstrated variable levels of LDLR expression in all cell lines, confirming their suitability as models to test LDLR-targeted nanotherapy delivery. Overall, our study reveals the LDLR pathway as a ubiquitous metabolic vulnerability in high grade gliomas across all ages, amenable to future consideration of LDL-mediated nanoparticle/drug delivery to potentially circumvent tumour heterogeneity.

Schlagwörter

Stichwörter der Autor:innen

high grade gliomalow-density lipoproteinnanotherapyperivascular

Autor:innen und Institutionen

  • Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK.
  • Department of Mechanical Engineering and Material Science, School of Engineering, Duke University, Durham, NC 27708, USA.

ORCID-Profile: David Needham, Ruman Rahman

Förderung

  • Mr. Michael Hodgkinson

Zitieren

APA

Adekeye, A. O., Needham, D., & Rahman, R. (2023). Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High Grade Glioma Amenable for Nanotherapeutic Delivery. Pharmaceutics, 15(2), 599. https://doi.org/10.3390/pharmaceutics15020599

Vancouver

Adekeye AO, Needham D, Rahman R. Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High Grade Glioma Amenable for Nanotherapeutic Delivery. Pharmaceutics. 2023;15(2):599. doi:10.3390/pharmaceutics15020599

BibTeX
@article{Adekeye2023,
  author = {Adekeye, Adenike O and Needham, David and Rahman, Ruman},
  title = {Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High Grade Glioma Amenable for Nanotherapeutic Delivery},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {2},
  pages = {599},
  doi = {10.3390/pharmaceutics15020599}
}
Kostenlos starten →